Payment overview · 2025
General Payments
$37.34
2 reported records · 2 companies
Healthcare provider profile · identity verified
Daniel Robert Herleth, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FLORISSANT, MO · NPI 1235365776
Verified facts
What the public records show
CMS Open Payments records show Daniel Robert Herleth, M.D. received $37.34 in general payments during 2025 across 2 reported records.
Medtronic, Inc. accounted for 59.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.05 | 59.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.29 | 41.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $37.34 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
34 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
80 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1226 | 361 |
| Amlodipine Besylate | Amlodipine Besylate | 836 | 259 |
| Lisinopril | Lisinopril | 539 | 158 |
| Metformin Hcl | Metformin Hcl | 399 | 116 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 349 | 106 |
| Fluticasone Propionate | Fluticasone Propionate | 316 | 120 |
| Losartan Potassium | Losartan Potassium | 313 | 103 |
| Furosemide | Furosemide | 310 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 304 | 85 |
| Gabapentin | Gabapentin | 285 | 88 |
| Omeprazole | Omeprazole | 275 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 274 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 269 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 269 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 244 | 72 |
| Glimepiride | Glimepiride | 231 | 67 |
| Potassium Chloride | Potassium Chloride | 209 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 56 |
| Simvastatin | Simvastatin | 173 | 47 |
| Allopurinol | Allopurinol | 169 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 163 | 49 |
| Carvedilol | Carvedilol | 154 | 50 |
| Meloxicam | Meloxicam | 151 | 56 |
| Trazodone Hcl | Trazodone Hcl | 147 | 58 |
| Montelukast Sodium | Montelukast Sodium | 146 | 46 |
| Jardiance | Empagliflozin | 143 | 34 |
| Eliquis | Apixaban | 139 | 29 |
| Famotidine | Famotidine | 136 | 37 |
| Ezetimibe | Ezetimibe | 132 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 36 |
| Donepezil Hcl | Donepezil Hcl | 123 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 40 |
| Baclofen | Baclofen | 116 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 113 | 47 |
| Azelastine Hcl | Azelastine Hcl | 111 | 52 |
| Mirtazapine | Mirtazapine | 110 | 35 |
| Alendronate Sodium | Alendronate Sodium | 104 | 31 |
| Ozempic | Semaglutide | 101 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 100 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 32 |
| Lovastatin | Lovastatin | 88 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 84 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 39 |
| Sertraline Hcl | Sertraline Hcl | 82 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 33 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 81 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 28 |
| Nortriptyline Hcl | Nortriptyline Hcl | 77 | 31 |
| Metformin Hcl Er | Metformin Hcl | 74 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 19 |
| Januvia | Sitagliptin Phosphate | 68 | 17 |
| Spironolactone | Spironolactone | 68 | 23 |
| Alprazolam | Alprazolam | 67 | 17 |
| Farxiga | Dapagliflozin Propanediol | 67 | 21 |
| Prednisone | Prednisone | 67 | 42 |
| Chlorthalidone | Chlorthalidone | 66 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 62 | 16 |
| Valsartan | Valsartan | 61 | 14 |
| Glipizide | Glipizide | 58 | 19 |
| Ibuprofen | Ibuprofen | 57 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 15 |
| Nifedipine Er | Nifedipine | 55 | 16 |
| Finasteride | Finasteride | 52 | 17 |
| Celecoxib | Celecoxib | 51 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 50 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 48 | 14 |
| Cephalexin | Cephalexin | 46 | 39 |
| Methylprednisolone | Methylprednisolone | 46 | 43 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 14 |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Hydrocortisone | Hydrocortisone | 43 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 13 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | 17 |
| Clonidine Hcl | Clonidine Hcl | 40 | 14 |
| Atenolol | Atenolol | 37 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 11 |
| Methocarbamol | Methocarbamol | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 35 | 21 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 34 | 34 |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 33 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | 12 |
| Colchicine | Colchicine | 29 | suppressed |
| Linzess | Linaclotide | 29 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Klor-Con M20 | Potassium Chloride | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | 11 |
| Memantine Hcl | Memantine Hcl | 27 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | 11 |
| Naproxen | Naproxen | 26 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 20 |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 15 |
| Glipizide Er | Glipizide | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 15 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Folic Acid | Folic Acid | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 16 |
| Irbesartan | Irbesartan | 16 | suppressed |
| Klayesta | Nystatin | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Etodolac | Etodolac | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $37.34 · 2 records | Medtronic, Inc. | AREXVY, INCEPTIV, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error